Quick Answer
PROKIDNEY CORP. reported Cash and Equivalents of $108.54 million for fiscal year 2025.
PROKIDNEY CORP. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $108.54M | +9.5% |
| 2024 | $99.12M | +63.4% |
| 2023 | $60.65M | -87.6% |
| 2022 | $490.25M | +2284.7% |
| 2021 | $20.56M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $95.32M | -11.8% | +12.2% |
| June 30, 2025 | $84.94M | -60.4% | -13.2% |
| March 31, 2025 | $97.81M | +15.9% | -1.3% |
| December 31, 2024 | $99.12M | +63.4% | -8.3% |
| September 30, 2024 | $108.09M | -43.5% | -49.6% |
| June 30, 2024 | $214.51M | -11.9% | +154.2% |
| March 31, 2024 | $84.39M | -68.9% | +39.1% |
| December 31, 2023 | $60.65M | -87.6% | -68.3% |
- PROKIDNEY CORP. showed an increase of +9.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, PROKIDNEY CORP.’s cash and equivalents has grown by 428.0% (from $20.56 million to $108.54 million).
- The most recent figure is from PROKIDNEY CORP.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: